Enregistré dans:
Détails bibliographiques
Auteurs principaux: Huan, Fei, Gao, Shuai, Gu, Yi, Ni, Lingna, Wu, Mingxuan, Li, Yongpeng, Liu, Meng, Yang, Yang, Xiao, Anfeng, Liu, Guangming
Format: Artículo científico
Langue:en
Publié: Clinical reviews in allergy & immunology 2025
Sujets:
Accès en ligne:https://pubmed.ncbi.nlm.nih.gov/40198416/
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
Table des matières:
  • Molecular Allergology: Epitope Discovery and Its Application for Allergen-Specific Immunotherapy of Food Allergy. Huan, Fei Gao, Shuai Gu, Yi Ni, Lingna Wu, Mingxuan Li, Yongpeng Liu, Meng Yang, Yang Xiao, Anfeng Liu, Guangming Humans Food Hypersensitivity Allergens Desensitization, Immunologic Animals Epitopes, T-Lymphocyte Epitopes, B-Lymphocyte Epitopes Computational Biology Epitope Mapping The prevalence of food allergy continues to rise, posing a significant burden on health and quality of life. Research on antigenic epitope identification and hypoallergenic agent design is advancing allergen-specific immunotherapy (AIT). This review focuses on food allergens from the perspective of molecular allergology, provides an overview of integration of bioinformatics and experimental validation for epitope identification, highlights hypoallergenic agents designed based on epitope information, and offers a valuable guidance to the application of hypoallergenic agents in AIT. With the development of molecular allergology, the characterization of the amino acid sequence and structure of the allergen at the molecular level facilitates T-/B-cell epitope identification. Alignment of the identified epitopes in food allergens revealed that the amino acid sequence of T-/B-cell epitopes barely overlapped, providing crucial data to design allergen molecules as a promising form for treating (FA) food allergy. Manipulating antigenic epitopes can reduce the allergenicity of allergens to obtain hypoallergenic agents, thereby minimizing the severe side effects associated with AIT. Currently, hypoallergenic agents are mainly developed through synthetic epitope peptides, genetic engineering, or food processing methods based on the identified epitope. New strategies such as DNA vaccines, signaling molecules coupling, and nanoparticles are emerging to improve efficiency. Although significant progress has been made in designing hypoallergenic agents for AIT, the challenge in clinical translation is to determine the appropriate dose and duration of treatment to induce long-term immune tolerance.